Piper Sandler Cuts PT on AbbVie Inc. (ABBV) Ahead of Quarterly Results

AbbVie Inc. (NYSE:ABBV) is one of the best stem cell therapy stocks to buy. On April 23, Piper Sandler cut the price target on AbbVie Inc. (NYSE:ABBV) to $294 from $299 while reaffirming an Overweight rating on the shares. The rating update came ahead of the quarterly results, with the firm saying that the company has become a bit controversial. Despite that, Piper is making a case for why there is no need for investors to worry, as the primary worry on AbbVie Inc. (NYSE:ABBV), as seen by the firm, is driven in part by the rollout of oral IL-23-directed treatment Icotyde by Johnson & Johnson in the psoriasis setting, along with how it could impact the trajectory of Skyrizi.

Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally

The firm would anticipate that Icotyde will likely expand the overall footprint of the IL-23 category, adding that Skyrizi penetration in inflammatory bowel disease is still quite low. It also stated that although the consensus estimates on Skyrizi may have caught up with its growth trajectory, there are other parts of the business where that is not the case.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.